Ultragenyx Pharmaceutical (STU:UP0) Interest Expense : €-61.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ultragenyx Pharmaceutical's interest expense for the three months ended in Mar. 2024 was € -14.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-61.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ultragenyx Pharmaceutical's Operating Income for the three months ended in Mar. 2024 was € -152.1 Mil. Ultragenyx Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was € -14.6 Mil. Ultragenyx Pharmaceutical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ultragenyx Pharmaceutical Interest Expense Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Interest Expense Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.02

-27.37

-26.04

-40.61

-60.53

Ultragenyx Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-14.60	-14.19	-16.55	-15.89	-14.58

Ultragenyx Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-61.2 Mil.

Ultragenyx Pharmaceutical (STU:UP0) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ultragenyx Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was €-14.6 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-152.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €25.7 Mil.

Ultragenyx Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Ultragenyx Pharmaceutical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ultragenyx Pharmaceutical (STU:UP0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RARE:USA RARE:Mexico

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines